000168126 001__ 168126
000168126 005__ 20260130122620.0
000168126 0247_ $$2doi$$a10.1111/vox.12860
000168126 0248_ $$2sideral$$a116879
000168126 037__ $$aART-2020-116879
000168126 041__ $$aeng
000168126 100__ $$aGorria, Carlos
000168126 245__ $$aImpact of implementing pathogen reduction technologies for platelets on reducing outdates
000168126 260__ $$c2020
000168126 5060_ $$aAccess copy available to the general public$$fUnrestricted
000168126 5203_ $$aBackground and Objectives: Applying pathogen reduction technologies (PRT) to platelets can extend their shelf life from 5 to 7 days, but there have been few systematic studies of the repercussions of such technologies on outdate rates. Material and Methods: The benefits in terms of outdate rates of applying PRT to platelets are studied via a mathematical simulation. Specifically, statistical methods are used to determine the daily production rate needed to meet demand while not exceeding a maximum amount set as a result of limitations on donations and while assuring a minimum daily stock. Results: The results show that a 2-day extension in the shelf life of platelet concentrates (PC) results in reductions in outdates ranging from 88·4% to 100% at the production centres analysed. It may be the case for budgetary reasons that only part of the PCs produced can be treated. This being so, we show that if the proportion treated per annum exceeds 25% the best option is to treat part of the output every day, otherwise, it is preferable to concentrate treatment on the last two production days of the week. Conclusions: Extending the shelf life of PC from five to seven days and setting up suitable production logistics can drastically reduce outdates at production centres. If only a part of all PCs is treated, the best choices are to distribute PRT overall production days or, if the percentage of PCs treated is very low, to apply PRT on the days preceding the weekend break.
000168126 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/MTM2017-83812-P
000168126 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000168126 590__ $$a2.144$$b2020
000168126 591__ $$aHEMATOLOGY$$b62 / 76 = 0.816$$c2020$$dQ4$$eT3
000168126 592__ $$a0.68$$b2020
000168126 593__ $$aMedicine (miscellaneous)$$c2020$$dQ2
000168126 593__ $$aHematology$$c2020$$dQ2
000168126 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000168126 700__ $$aLabata, Gorka
000168126 700__ $$aLezaun, Mikel
000168126 700__ $$0(orcid)0000-0002-7615-2559$$aLópez, F. Javier$$uUniversidad de Zaragoza
000168126 700__ $$aPérez Aliaga, Ana Isabel
000168126 700__ $$aPérez Vaquero, Miguel Ángel
000168126 7102_ $$12007$$2265$$aUniversidad de Zaragoza$$bDpto. Métodos Estadísticos$$cÁrea Estadís. Investig. Opera.
000168126 773__ $$g115, 2 (2020), 167-173$$pVox sang.$$tVox sanguinis$$x0042-9007
000168126 8564_ $$s1197086$$uhttps://zaguan.unizar.es/record/168126/files/texto_completo.pdf$$yPostprint
000168126 8564_ $$s3128695$$uhttps://zaguan.unizar.es/record/168126/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000168126 909CO $$ooai:zaguan.unizar.es:168126$$particulos$$pdriver
000168126 951__ $$a2026-01-30-12:22:20
000168126 980__ $$aARTICLE